Therapeutic flavonoid based antiviral agents

Abstract

The world is plagued with several viruses some of which have prevention and treatment tools available, while every so often a new strain will show up without sensitivity to existing drugs. The present invention provides plant-based flavonoid pharmaceutical compositions for inhibition of kinases, particularly phosphatidylinositol-4-kinases (PI4Kiiiβ), AAK1, BIKE, GAK and other transcription factors required for viral entry, replication and survival, and consequent for prevention and treatment of RNA viruses including but not limited to adenoviruses, alphaviruses, coronaviruses, enteroviruses, flaviviruses, hepatitis, herpes, influenza viruses, measles, picornaviruses, vesicular stomatitis and associated disorders. A method for synthesizing the flavonoids and formulation into therapeutic products are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION(S)[0001]The present application derives priority from U.S. provisional application No. 62 / 993,236 filed 23 Mar. 2020, and is a continuation of U.S. patent application Ser. No. 16 / 321,333 filed 19 Mar. 2019, which is the national stage entry of PCT / US17 / 44153, which in turn derives priority from U.S. Provisional Patent Application 62 / 367,345 filed 27 Jul. 2016, the entirety of which is incorporated herein by reference.BACKGROUND OF THE INVENTION1. Field of the Invention[0002]The present invention relates to flavonoid derivatives and, more particularly, to plant flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating viral infections2. Description of the Background[0003]Virus are small infectious organisms—much smaller than a fungus or bacterium—that must invade a living cell to reproduce (replicate). The virus attaches to a cell (called the host cell), ent...

AI Technical Summary

Benefits of technology

The invention provides a therapeutic flavonoid composition that can prevent and treat RNA viral infections including adenovirus, alphavirus, coronavirus, enterovirus, flavivirus, hepatitis, herpes, influenza viruses, measles, picomavirus, vesicular stomatitis and associated disorders. The flavonoid-based pharmaceutical composition has a specific structure and can be isolated from raw plant material. The patent also includes a method of treatment using the specific plant-based flavonoid pharmaceutical compositions.

Problems solved by technology

RNA viruses, particularly retroviruses, are prone to mutate.

Sometimes the infected cell loses control over normal cell division and becomes cancerous.

However, in some people, it eventually results in cirrhosis (severe scarring of the liver), liver failure, and sometimes liver cancer.

While the majority of COVID-19 infections result in mild symptoms, some progress to pneumonia and multi-organ failure.

Currently, there is no well-established treatment for SARS-CoV-2 despite the deployment of several vaccines against the virus.

This component of treatment is a burden to the health system capacity and societies look to “flatten the curve” in order to keep the speed at which new cases occur in a downward direction.

According to most recent statistics from the World Health Organization the global burden of HCV is as follows:71 million people globally have chronic hepatitis C infection.A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer.350,000 to 500,000 people die each year from hepatitis C-related liver diseases.Antiviral medicines can cure hepatitis C infection, but access to diagnosis and treatment is low as effective drugs are very expensive and out of the reach of many especially in developing countries.Antiviral treatment is successful in 50-90% of persons treated, depending on the treatment used, and has also been shown to reduce the development of liver cancer and cirrhosis.

The burden is accelerating access to hepatitis C diagnostics and treatment and overcoming barriers in low and middle-income countries.

Unfortunately, the efficacies of new direct-acting antivirals (DAAs) is unknown in some groups of patients with different subtypes of the virus as well as those with advance cirrhosis.

Images